文献速递头痛与眩晕

泼尼松与安慰剂短期预防发作性丛集性头痛的随机对照试验

Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial.
PubMed 文献 · Lancet Neurol · 2020-11-24

这项在德国10个头痛中心开展的多中心、双盲、随机对照试验,纳入发作性丛集性头痛患者,比较口服泼尼松(100 mg×5天,后每3天减20 mg,共17天)与安慰剂在治疗第一周内头痛发作次数的差异。所有患者同时接受维拉帕米长期预防。

要点

  • 泼尼松可减少发作性丛集性头痛患者第一周内的发作次数。
  • 泼尼松组与安慰剂组不良事件发生率相似,均为71%。
  • 研究支持泼尼松与维拉帕米滴定并行作为一线短期预防。

核心结论

  • 口服泼尼松是发作性丛集性头痛患者的有效短期预防治疗。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,在德国10个专科头痛中心进行。
  • 纳入18至65岁、当前疼痛发作不超过30天的发作性丛集性头痛患者。
  • 116例患者随机分配(泼尼松组57例,安慰剂组59例),109例纳入改良意向治疗分析(泼尼松组53例,安慰剂组56例)。

主要发现

  • 两组各有71%的患者报告不良事件,泼尼松组最常见为头痛、心悸、头晕和恶心。
  • 安慰剂组发生2例严重不良事件(腹股沟疝和丛集性头痛严重恶化)。

关键数值与推荐

  • 泼尼松用法:口服100 mg每日一次,共5天,随后每3天减20 mg,总暴露17天。
  • 所有患者同时口服维拉帕米长期预防,起始40 mg每日三次,至第19天增至120 mg每日三次。
  • 主要终点为治疗第一周内平均发作次数,发作定义为单侧头痛,数字评分量表强度至少5分(中重度)。

临床怎么用

  • 对于发作性丛集性头痛患者,可考虑口服泼尼松作为短期预防,与维拉帕米滴定并行。
  • 泼尼松的疗效与其他长期预防药物联合使用仍需进一步研究。

局限性

  • 研究因招募缓慢和资金到期而提前终止。
  • 样本量较小,改良意向治疗分析仅109例。
  • 未评估泼尼松与其他长期预防药物联合使用的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prednisone is commonly used for initial short-term therapy of episodic cluster headaches before preventive medication such as verapamil becomes effective, but this strategy has not been tested in large randomised trials. We aimed to access the safety and efficacy of this treatment approach. METHODS: This study was a multicentre, randomised, double-blind, placebo-controlled trial done in ten specialised headache centres in Germany. Patients with episodic cluster headaches who were aged between 18 and 65 years and within a current pain episode for not more than 30 days, received 100 mg oral prednisone for 5 days followed by tapering of 20 mg every 3 days, or matching placebo (17 days total exposure). All patients received oral verapamil for long-term prevention, starting with 40 mg three times daily and increasing to 120 mg three times daily by day 19; patients then continued with verapamil 120 mg throughout the study. Randomisation was computer-generated at a 1:1 ratio by use of an interactive web-response system, with stratification according to age, sex, and participating site. Participants, investigators, and those assessing outcomes were unaware of treatment allocation. The primary endpoint was the mean number of attacks within the first week of treatment with prednisone compared with placebo. An attack was defined as a unilateral headache with moderate-to-severe intensity of at least five on a numerical rating scale. All efficacy and safety analyses were done in the modified intention-to-treat (mITT) population, which consisted of all patients who had been randomly assigned to a trial group and received at least one dose of prednisone or placebo. The study was stopped early due to slow recruitment and expired funding. The study was registered with EudraCT (2011-006204-13) and with the German Clinical Trials Register (DRKS00004716). FINDINGS: Between April 5, 2013, and Jan 11, 2018, 118 patients were enrolled in the study. Two patients dropped out immediately and 116 patients were randomly assigned (57 patients to prednisone and 59 patients to placebo); 109 patients were included in the mITT analysis (53 patients assigned to prednisone and 56 patients assigned to placebo). Participants in the prednisone group had a mean of 7·1 (SD 6·5) attacks within the first week compared with 9·5 (6·0) attacks in the placebo group (difference -2·4 attacks, 95% CI -4·8 to -0·03; p=0·002). Two serious adverse events occurred, both in the placebo group (inguinal hernia and severe deterioration of cluster headache). A total of 270 adverse events were observed: in the prednisone group, 37 (71%) of 52 patients reported 135 adverse events (most common were headache, palpitations, dizziness, and nausea) and in the placebo group, 39 (71%) of 55 patients had 135 adverse events (most common were nausea, dizziness, and headache). INTERPRETATION: Oral prednisone was an effective short-term preventive therapy in our population of patients with episodic cluster headache. Our findings support the use of prednisone as a first-line treatment in parallel to the up-titration of verapamil, although the efficacy of prednisone alongside other long-term prevention requires additional investigation. FUNDING: German Federal Ministry for Education and Research.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Obermann M, Nägel S, Ose C, et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. Lancet Neurol. 2020. PMID: 33245858. doi:10.1016/S1474-4422(20)30363-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。